1.Date of the resolution by the board of directors or
shareholders' meeting, or of the decision by the company:2022/06/16
2.Type (ex-rights or ex-dividend) (please write "Ex-rights",
"Ex-dividend", or "Ex-rights and dividend"):Ex-dividend
3.Type and monetary amount of dividend distribution:
The amount of cash dividends is NT$42,724,800(NT$2 per share)
4.Ex-rights (Ex-dividend) date:2022/07/06
5.Last date before book closure:2022/07/07
6.Book closure starting date:2022/07/08
7.Book closure ending date:2022/07/12
8.Ex-rights (Ex-dividend) record date:2022/07/12
9.Deadline for applying the conversion of the debt voucher:NA
10.The closure period for the conversion of the debt voucher will
start from the date:NA
11.The closure period for the conversion of the debt voucher will
end on the date:NA
12.Payment date of cash dividend distribution:2022/07/28
13.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sofiva Genomics Co. Ltd. published this content on 16 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 June 2022 07:22:09 UTC.
Sofiva Genomics Co Ltd is a Taiwan-based company mainly engaged in provision of deoxyribonucleic acid (DNA) testing services. The Company's DNA testing services mainly contain reproductive medicine testing, pregnant women testing, newborn testing, rare disease genetic testing, personalized genetic testing, cancer genetic testing, and genetic counseling services. Reproductive Medicine testing is pre-implantation genetic diagnosis for embryos. Pregnant women testing services predict the occurrence of preeclampsia and provide prenatal diagnosis. Neonatal testing services provide neonatal hearing loss genetic test, respiratory distress syndrome test, congenital cytomegalovirus infection test service. Personalized genetic testing services includes human papilloma virus screening, paternity testing, telomere testing, chronic disease and cardiovascular disease and other genetic research. Cancer genetic testing services is applied to cancer patients.